About the Lab
The Tumor Angiogenesis and Vascular Biology Laboratory of Debabrata (Dev) Mukhopadhyay, Ph.D., at Mayo Clinic investigates the role of angiogenesis-related factors in tumor formation and development of cardiovascular diseases.
Growth of solid tumors beyond 1 to 2 millimeters in diameter requires the induction and maintenance of a new blood supply (angiogenesis). Failure to induce an angiogenic response can result in tumor dormancy, and interference with an established blood supply can lead to necrosis or apoptosis of tumor cells and tumor regression.
Angiogenesis is a tightly regulated process maintained by a balance of positive and negative regulatory pathways. Because of its central role in abnormal tissue growth (neoplasia) and other non-neoplastic disorders and in normal adult physiology, angiogenesis has attracted a great deal of scientific interest.
Tumor angiogenesis is thought to result from the secretion of angiogenesis factors by tumor cells. These include growth factors, cytokines and a number of small molecules.
Growth factors possessing angiogenic activity include fibroblast growth factor (FGF), platelet-derived growth factor (PDGF), vascular permeability factor/vascular endothelial growth factor (VPF/VEGF). Angiogenic growth factors have been shown to be involved in tissue metabolism and pathogenesis of cardiovascular diseases, including heart failure.
Dr. Mukhopadhyay's Tumor Angiogenesis and Vascular Biology Lab conducts research in these areas:
- Regulation and function of angiogenic growth factors
- Tumor stroma
- Endothelial biology
- Cardiovascular biology
- Cell signaling
- Preclinical models for tumor biology, angiogenesis and cardiovascular diseases
- Angiogenesis and the immune system
The Tumor Angiogenesis and Vascular Biology Lab works closely with other groups and organizations within Mayo Clinic, including: